118 related articles for article (PubMed ID: 8704199)
1. Humoral immune response limits gene therapy in canine MPS I.
Shull R; Lu X; Dubé I; Lutzko C; Kruth S; Abrams-Ogg A; Kiem HP; Goehle S; Schuening F; Millan C; Carter R
Blood; 1996 Jul; 88(1):377-9. PubMed ID: 8704199
[No Abstract] [Full Text] [Related]
2. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
[TBL] [Abstract][Full Text] [Related]
3. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency.
Lutzko C; Kruth S; Abrams-Ogg AC; Lau K; Li L; Clark BR; Ruedy C; Nanji S; Foster R; Kohn D; Shull R; Dubé ID
Blood; 1999 Mar; 93(6):1895-905. PubMed ID: 10068662
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
5. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
[TBL] [Abstract][Full Text] [Related]
6. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME
Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321
[TBL] [Abstract][Full Text] [Related]
8. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
[TBL] [Abstract][Full Text] [Related]
9. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.
Meertens L; Zhao Y; Rosic-Kablar S; Li L; Chan K; Dobson H; Gartley C; Lutzko C; Hopwood J; Kohn D; Kruth S; Hough MR; Dubé ID
Hum Gene Ther; 2002 Oct; 13(15):1809-20. PubMed ID: 12396614
[TBL] [Abstract][Full Text] [Related]
10. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
[TBL] [Abstract][Full Text] [Related]
11. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
[TBL] [Abstract][Full Text] [Related]
12. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
[TBL] [Abstract][Full Text] [Related]
13. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
[TBL] [Abstract][Full Text] [Related]
14. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
[TBL] [Abstract][Full Text] [Related]
15. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
[TBL] [Abstract][Full Text] [Related]
16. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
17. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
Metcalf JA; Ma X; Linders B; Wu S; Schambach A; Ohlemiller KK; Kovacs A; Bigg M; He L; Tollefsen DM; Ponder KP
Mol Ther; 2010 Feb; 18(2):334-42. PubMed ID: 19844196
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in mucopolysaccharidosis type I.
Miebach E
Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
[TBL] [Abstract][Full Text] [Related]
19. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
[TBL] [Abstract][Full Text] [Related]
20. Common antigenicity for two glycosidases.
Kakavanos R; Lehn P; Callebaut I; Meikle PJ; Parkinson-Lawrence EJ; Hopwood JJ; Brooks DA
FEBS Lett; 2006 Jan; 580(1):87-92. PubMed ID: 16359666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
